Where is Immedica located?

Immedica is headquartered in Stockholm, Sweden. It is registered at SUITE 4, 7TH FLOOR,50 BROADWAY,LONDON,UNITED KINGDOM,SW1H 0DB.

How many employees does Immedica have?

As of Apr 30, 2026, the latest employee count at Immedica is 178.

Is Immedica a funded company?

Immedica is a funded company, having raised a total of $***** in its 1st and only funding round.

Where does Immedica rank among its competitors?

Immedica ranks 31st amongst 71 active competitors, of which 18 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Anocca, which secured $46M in Aug, 2025.

Who are the top competitors of Immedica?

Immedica's top competitors include BeiGene, Moderna and AmerisourceBergen. Among them, Anocca secured the most recent funding round in August, 2025.

Immedica - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Immedica is a developer of therapeutic agents for treating oncology, neurology, infectious diseases, ophthalmology, and inflammatory. The company has developed drugs (Arlevert and Vertisan) for treating Vertigo of various origins. The company has also developed drugs for corneal neovascularization.

Website: www.immedica.com/en
Registered Address: SUITE 4, 7TH FLOOR,50 BROADWAY,LONDON,UNITED KINGDOM,SW1H 0DB

Key Metrics

Founded Year

2017

Location

Stockholm, Sweden

Stage

Acquired

Investors

Impilo

Ranked

31^st among 71 active competitors

Employee Count

178 as on Apr 30, 2026

Investment & Acquisitions

Neurocrine & 1 more

Similar Companies

Jazz Pharmaceuticals & 2967 more

Exit Details

Acquired by KKR (Apr 23, 2024)

View Immedica's full profile

Immedica is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Immedica Pharma Ab CIN: 0766.287.429 , Belgium, Active	Apr 01, 2021	-	-	-
IMMEDICA PHARMA UK LTD CIN: 11457556 , United Kingdom, Active	Jul 09, 2018	-	7 (As on Dec 31, 2024)

Immedica got acquired by KKR and Impilo on Apr 23, 2024.

Click here to take a look at Immedica's acquisition in detail

Immedica is a funded company. Immedica has 1 institutional investor.

View details of Immedica's funding rounds and investors

Immedica's employee count trend

Immedica has 178 employees as of Apr 26. Here is Immedica's employee count trend over the years:

Uncover Immedica's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Immedica include BeiGene, Moderna and AmerisourceBergen. Here is the list of Top 10 competitors of Immedica, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	81/100
2nd	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 31 others	71/100
3rd	AmerisourceBergen 1985, Chesterbrook (United States), Public	Drug Corporation	-	nextGENE Capital, Walgreens Boots Alliance ... & 4 others	71/100
4th	Tesaro 2010, Waltham (United States), Acquired	Global biopharma innovating medicines in respiratory, immunology, oncology, HIV, and infectious diseases	$161M	Kleiner Perkins, New Enterprise Associates ... & 14 others	66/100
5th	Galapagos 1999, Mechelen (Belgium), Public	Developer of small molecule drugs for immunology and oncology	$136M	Eiffel Investment Group, Abingworth & 17 others	61/100
6th	Asgard Therapeutics 2017, Lund (Sweden), Series A	Developer of cancer immunotherapeutic solutions based on direct cell reprogramming	$39.8M	Johnson & Johnson Innovation, RV Invest & 6 others	60/100
7th	Daiichi Sankyo 2005, Chuo City (Japan), Public	Developer of drugs to address diverse medical needs	-	GrandEst, BioVaria	58/100
8th	Anocca 2014, Sodertalje (Sweden), Series D	Deevloper of personalized immunotherapeutics for oncology, autoimmune and inflammatory diseases	$166M	Mellby Gård, Danske Bank & 7 others	58/100
9th	Affibody 1998, Solna (Sweden), Series D	Developer of antibody mimetic and protein based drug for the treatment of multiple diseases	$43.3M	AP3, International Biotechnology Trust & 9 others	58/100
10th	Alligator Bioscience 2001, Lund (Sweden), Public	Developer of antibody-based immunotherapies for the treatment of cancer	$10M	Sunstone, Allegro Investment Fund & 8 others	56/100
31st	Immedica 2017, Stockholm (Sweden), Acquired	Developer of therapeutic agents for multiple diseases	-	Impilo	41/100